Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jan;314(1):e232650.
doi: 10.1148/radiol.232650.

CT, MRI, and FDG PET/CT in the Assessment of Lymph Node Involvement in Pediatric Hodgkin Lymphoma: An Expert Consensus Definition by an International Collaboration on Staging Evaluation and Response Criteria Harmonization for Children, Adolescent, and Young Adult Hodgkin Lymphoma (SEARCH for CAYAHL)

Affiliations
Review

CT, MRI, and FDG PET/CT in the Assessment of Lymph Node Involvement in Pediatric Hodgkin Lymphoma: An Expert Consensus Definition by an International Collaboration on Staging Evaluation and Response Criteria Harmonization for Children, Adolescent, and Young Adult Hodgkin Lymphoma (SEARCH for CAYAHL)

Dietrich Stoevesandt et al. Radiology. 2025 Jan.

Abstract

Staging of pediatric Hodgkin lymphoma is currently based on the Ann Arbor classification, incorporating the Cotswold modifications and the Lugano classification. The Cotswold modifications provide guidelines for the use of CT and MRI. The Lugano classification emphasizes the importance of CT and PET/CT in evaluating both Hodgkin lymphoma and non-Hodgkin lymphoma but focuses on adult patients. This article presents consensus guidelines that extend the traditional classifications used for adult Hodgkin lymphoma staging and provide rigorous definitions of lymph node groups based on MRI, CT, and fluorodeoxyglucose PET/CT findings. This allows consistent terminology and definitions, using metabolic and morphologic imaging to identify affected lymph nodes or extranodal regions and organs. The pattern of involvement, together with other individual risk factors, determines treatment strategy. In case of inadequate response to chemotherapy, radiation therapy is often required. Standardization of staging definitions for pediatric Hodgkin lymphoma is necessary for comparing treatment outcomes between North American and European clinical trials and a prerequisite for clear communication during tumor boards and central review. This comprehensive imaging atlas is intended to provide regional criteria for nodal involvement and to serve as a standardized guide for the anatomic assignment of lymph node involvement in pediatric Hodgkin lymphoma.

PubMed Disclaimer

Conflict of interest statement

Disclosures of conflicts of interest: D.S. No relevant relationships. J.S. Support from the St Jude Children’s Research Hospital for attending the Fifth International Symposium on Childhood, Adolescent, and Young Adult Hodgkin Lymphoma (ISCAYAHL). J.M.B. No relevant relationships. L.K. No relevant relationships. K.M.M. Member of Organizing Committee for the 2024 international meeting of ISCAYAHL (International Symposium on Childhood, Adolescent, and Young Adult Hodgkin Lymphoma). J.E.F. No relevant relationships. T.W.G. No relevant relationships. C.M.K. Institution received a research grant from Merck Pharma, EuroNet PHL scientific secretary (unpaid). S.Y.C. Member of Radiology editorial board. D.K. The EuroNet-PHL-C2 trial was supported by Deutsche Krebshilfe; until October 2023 has been the chairperson of the GPOH-HD Study Group elected by the German Childhood Cancer Society. R.K. No relevant relationships. K.M.K. Institution received payments for author’s effort related to this research through the Children's Oncology Group‘s grant from NIH/NCI; institution receives payment related to Hodgkin lymphoma research through the CDRMP Research Program and through the Children's Oncology Group and supported by Merck; author received honoraria for lectures on Hodgkin lymphoma support through continuing medical education companies; author received support for attending the American Society of Pediatric Hematology/Oncology annual meeting in 2023 for presentation on pediatric Hodgkin lymphoma; chair of the Pediatric Hodgkin lymphoma NCCN Guidelines Panel (unpaid); scientific advisory board member for Seagen (unpaid, term ended in 2023); member of the Scientific Advisory Board of the Lymphoma Research Foundation (unpaid). T.P. No relevant relationships. D.V. Vice president of German Society of Radiation Oncology. B.S.H. Received payment for educational CME development on radiation use on AHOD 1331; Children's Oncology Group funded travel to semi-annual meetings as the lead radiation oncologist on the pediatric Hodgkin lymphoma subcommittee; scientific advisory board for a Children’s Oncology Group study 1822 with Merck, contracted between Mayo Clinic and COG; NRG Hematologic Malignancy Working Group co-chair (unpaid). K.D. No relevant relationships. S.D.V. Received payment for expert testimony (2022 Pulaski County Court, No. 60CV-20-2053, legal fees from Hugh Crisp, LLC, and Anderson, Murphy, Hopkins, LLC; travel support for attending and presenting at the Eighth International Symposium on Pediatric Solid Tumors: Neuroblastoma in Tübingen, Germany.

References

    1. Hodgkin . On some Morbid Appearances of the Absorbent Glands and Spleen . Med Chir Trans 1832. ; 17 : 68 – 114 . - PMC - PubMed
    1. Schellong G , Brämswig J , Ludwig R , et al. . Combined treatment strategy in over 200 children with Hodgkin's disease: graduated chemotherapy, involved field irradiation with low dosage and selective splenectomy. A report of the cooperative therapy study DAL-HD-82 [in German] . Klin Padiatr 1986. ; 198 ( 3 ): 137 – 146 . - PubMed
    1. Weiner MA , Leventhal B , Brecher ML , et al. . Randomized study of intensive MOPP-ABVD with or without low-dose total-nodal radiation therapy in the treatment of stages IIB, IIIA2, IIIB, and IV Hodgkin’s disease in pediatric patients: a Pediatric Oncology Group study . J Clin Oncol 1997. ; 15 ( 8 ): 2769 – 2779 . - PubMed
    1. Schellong G , Pötter R , Brämswig J , et al. . High cure rates and reduced long-term toxicity in pediatric Hodgkin’s disease: the German-Austrian multicenter trial DAL-HD-90. The German-Austrian Pediatric Hodgkin’s Disease Study Group . J Clin Oncol 1999. ; 17 ( 12 ): 3736 – 3744 . - PubMed
    1. Donaldson SS , Hudson MM , Lamborn KR , et al. . VAMP and low-dose, involved-field radiation for children and adolescents with favorable, early-stage Hodgkin’s disease: results of a prospective clinical trial . J Clin Oncol 2002. ; 20 ( 14 ): 3081 – 3087 . - PubMed

Substances